Skip to main content
| News

Qnami secures investment of 4 million Swiss francs

17.05.2021

Qnami has raised a total of 4 million Swiss francs from investors after successfully closing a Series A financing round. The Basel Area-based startup has developed a quantum microscope technology that has since been patented as well as producing the first commercial quantum microscope.

qnami team
The Qnami team with CEO Mathieu Munsch (fourth from left) (Img: Qnami)

Qnami has announced the successful closing of a Series A financing round in which the startup raised a total of 4 million Swiss francs in fresh capital. Qnami was founded in Basel in 2017 and is now based in Muttenz in the canton of Basel-Landschaft.

The financing round was led by the venture capitalists Runa Capital, which operates out of headquarters in both Silicon Valley and Europe, as well as SIT Capital, which is associated with the Schaffhausen Institute of Technology. The circle of investors included the venture capital companies Quantonation and Verve Ventures, which operate on a pan-European basis, in addition to the Bonn-based High-Tech Gründerfonds and the Cantonal Bank of Zurich.

With this fresh capital injection, Qnami intends to extend its patented quantum microscope technology into applications that will facilitate the design and production of quantum computers and spintronics devices. Furthermore, according to the press release issued by the company, the funds will be used to scale the market launch of the Qnami ProteusQ, the first commercial quantum microscope.

This device uses Qnami’s patented Quantilever diamond scanning probes. “We have gained good market traction with the launch of the ProteusQ and Quantilevers in the materials research setting”, explains Mathieu Munsch, co-founder and CEO of Qnami. “Top researchers already use Qnami’s technology to discover and describe the magnetic properties of new materials”, he adds.

According to Dmitry Galperin, General Partner at Runa Capital, the company is of the view that the technology could also be used for additional applications, including medical imaging and navigation, for example. Galperin is set to join the board of Qnami as a new member.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.